Elizabeth Schneider: Revolutionary Drug Shows Promise for Primary Ovarian Insufficiency
Elizabeth Schneider, Staff Product Marketing Manager at Illumina, shared a post on LinkedIn:
“Primary ovarian insufficiency (POI), in which the ovaries don’t mature and release eggs properly, affects about 3% of women under age 40 and typically causes infertility. But a drug already approved to treat kidney disease may one day help some of these people get pregnant, a research team reports today in Science.
In studies of mouse ovarian tissue and live mice, the drug, called finerenone, kick-started the growth of tiny egg-containing sacs, or follicles—a process that’s often defunct in people with POI. In a small clinical trial, people with POI who were given the drug went on to produce mature eggs that could be harvested, and some of the eggs were then successfully fertilized in the lab.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 8, 2026, 11:40Hugo Vankelecom: Innovative Organoid Models Transform Women’s Health Research
-
Feb 8, 2026, 11:20Mikhail Ruzaev: Redefining AMH and AFC: Insights on Embryo Euploidy
-
Feb 8, 2026, 02:49Put Your Skates On and Register for This ESHRE Webinar – ESHRE
-
Feb 8, 2026, 02:40Real-Time Nerve Mapping for Sciatic and Pudendal Endometriosis – Fertility and Sterility
-
Feb 7, 2026, 18:32Democratizing Access to Fertility Care for Every Journey – The Association of Reproductive Managers
-
Feb 7, 2026, 18:08Women’s Reproductive Health in Canada – Femtech Canada
-
Feb 7, 2026, 17:55Endometriosis Prevalence Study Reveals Alarming Trends – RBMO
-
Feb 7, 2026, 17:46RBMO Insights Issue 45 Now Available – RBMO
-
Feb 7, 2026, 16:36Ethics Committee Weighs in on PGT for Polygenic Disorders – Fertility and Sterility
